RPRX · Royalty Pharma plc
United States · RS rating 96 · As of 2026-11-03
| Price | 66.40 USD |
|---|---|
| 1-day change | -0.2% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 92 / 86 / 91 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 52 / 77 / 43 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -25.2% |
| Sales growth Q/Q | +2.1% |
| Distance from 52-week high | +1.2% |
| Market cap (USD) | $29.4B |